 PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Percent or Higher,1 Underscoring Need to Mitigate the Profound Impact Hearing Loss ... The post Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK sodium thiosulfate injectio... 